Immuno-Oncology | Specialty

The OncFive: Top Oncology Articles for the Week of 2/16

February 22nd 2025

FDA grants priority review to zongertinib in HER2-mutant NSCLC and dordaviprone for recurrent H3K27M+ diffuse glioma, and more from OncLive this week.

FDA Grants Breakthrough Therapy Designation to Petosemtamab Plus Pembrolizumab for PD-L1+ HNSCC

February 20th 2025

Petosemtamab/pembrolizumab received FDA breakthrough therapy designation for PD-L1–positive recurrent/metastatic head and neck squamous cell carcinoma.

Detalimogene Voraplasmid Produces Complete Responses in BCG-Unresponsive NMIBC With CIS

February 19th 2025

Detalimogene voraplasmid generated complete responses in BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ.

CBM588 Plus Cabozantinib/Nivolumab Shows Early Activity in Metastatic Renal Cell Carcinoma

February 15th 2025

CBM588 plus cabozantinib and nivolumab shows early efficacy in metastatic renal cell carcinoma.

Nivolumab Plus Relatlimab Fails to Improve RFS in Resected Stage III/IV Melanoma

February 14th 2025

Nivolumab plus relatlimab did not improve recurrence-free survival vs nivolumab in resected stage III/IV melanoma.

Oncology Experts Preview Top Abstracts From 2025 ASCO GU

February 12th 2025

Experts highlight the top presentations to watch for at the 2025 Genitourinary Cancers Symposium.

Pembrolizumab Provides Clinical Benefit in Previously Treated Advanced Clear Cell Gynecologic Cancer

February 9th 2025

Pembrolizumab warrants further evaluation in patients with previously treated advanced clear cell gynecologic cancer in a randomized clinical trial.

Gemogenovatucel-T Receives FDA RMAT Designation for Advanced HRP Ovarian Cancer

February 5th 2025

The FDA granted RMAT designation to gemogenovatucel-T for maintenance treatment after frontline chemotherapy in advanced HRP ovarian cancer.

Nivolumab/Ipilimumab Approaches EU Approval in Unresectable or Advanced HCC

January 31st 2025

The EMA’s CHMP has adopted a positive opinion regarding frontline nivolumab plus ipilimumab in unresectable or advanced hepatocellular carcinoma.

FDA Approval of Tislelizumab Plus Chemo Offers a New Option in Advanced Gastric/GEJ Adenocarcinoma

January 29th 2025

Marcia Cruz-Correa, MD, PhD, AGAF, FASGE, discusses the FDA approval of tislelizumab with chemotherapy for advanced gastric or GEJ adenocarcinoma.

The OncFive: Top Oncology Articles for the Week of 1/19

January 25th 2025

Treosulfan wins FDA approval for allHCT conditioning in AML and MDS, RP1/nivolumab gets priority review in melanoma, and more this week from OncLive.

Pembrolizumab Plus Lenvatinib and Chemo Misses OS End Point in Gastroesophageal Adenocarcinoma

January 24th 2025

OS was not improved with pembrolizumab plus lenvatinib and chemotherapy vs chemotherapy alone in advanced HER2-negative gastroesophageal adenocarcinoma.

FDA Grants Priority Review to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy

January 21st 2025

The FDA granted priority review to the BLA for RP1 plus nivolumab in advanced melanoma following progression on an anti–PD-1 agent.

The OncFive: Top Oncology Articles for the Week of 1/12

January 18th 2025

Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.

Clinical, Molecular Factors Correlate With pCR for Durvalumab/Trastuzumab/Pertuzumab in Early HER2+ Breast Cancer

January 15th 2025

Polly Niravath, MD, discusses data from an analysis conducted in a study of durvalumab, trastuzumab, and pertuzumab in early HER2-positive breast cancer.

NGS-Based xT CDx Test Is Now Commercially Available in United States for Solid Tumor Profiling

January 15th 2025

The xT CDx assay is now available nationwide in the United States for use in solid tumor profiling.

Nivolumab Plus Gemcitabine/Cisplatin Shows Favorable OS/PFS Trend in Asian Unresectable/Metastatic Urothelial Cancer Subpopulation

January 15th 2025

First-line nivolumab plus chemotherapy numerically improved survival vs chemotherapy alone in Asian patients with unresectable/metastatic urothelial cancer.

Adjuvant Nivolumab Plus Chemoradiotherapy Meets DFS End Point in Locally Advanced HNSCC

January 14th 2025

Adjuvant nivolumab plus chemoradiotherapy improved disease-free survival in resected, locally advanced head and neck squamous cell carcinoma.

FDA Approval of Subcutaneous Nivolumab Represents Paradigm Shift in Solid Tumor Management

January 13th 2025

Roxana S. Dronca, MD, discusses the FDA approval of subcutaneous nivolumab across solid tumor indications.

Neoadjuvant Niraparib Plus Dostarlimab Data Support Development of Non-Chemo Approaches in BRCA+, ER+ Breast Cancer

January 13th 2025

Erica L. Mayer, MD, MPH, responses with preoperative niraparib plus dostarlimab in patients with BRCA-mutant, ER-positive, HER2-negative breast cancer.